Business Daily from THE HINDU group of publications
Thursday, Jul 27, 2006


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Standards & Benchmarks
Lupin gets nod for psoriasis drug trial

Our Bureau

Mumbai , July 26

Lupin Ltd has received regulatory approval to conduct the second phase of human-trials on its prospective drug targeting psoriasis, a skin-related condition.

The Drug Controller General of India (DCGI) has given its approval to conduct Phase-II clinical trials for its psoriasis pure compound LL-4218 (Desoside-P), a note from Lupin said.

In Phase II trials, the prospective medicine is targeted at a sample-size of 100-500 human subjects infected with the disease. Lupin expects to begin clinical trials at about six centres immediately, a note from the company said. The total market for psoriasis is estimated to be in excess of $2 billion. The company also has three other new chemical entities in various stages of clinical trials, the note added.

More Stories on : Standards & Benchmarks | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Govt rejects RIL price for gas to RNRL


Bank guarantee could not be invoked if arbitration award is challenged: HC
Kirloskar Bros sheds stake in Kirloskar Copeland
ICI India set to merge Quest International with itself
Astra Micro to acquire Komoline
JCB plans Rs 350-cr expansion
Wireless medical monitoring for patients
Apollo, Johns Hopkins tie up for study on heart ailments
ONGC net rises
Himalaya Drug gets ISO-14001 certification
Lupin gets nod for psoriasis drug trial
Godrej Consumer mulls greenfield soap brands
`Bright prospects for electric vehicles'
Mahindra & Mahindra plans to launch CNG bus
Hikal realigns pharma strategy
BOC India to explore opportunities in petrochem
Reliance diesel, motor spirit sales drop
ITH Q1 profit after tax at Rs 1.73 cr
SAIL likely to get part-time Chairman
How Dr Reddy's became a $1-b company


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line